[Opinion]Research and development accounts for only about 17 percent of total spending at most big pharma companies. Faculty Associate Gerard Anderson is quoted.
News Archive
How To End The Scourge Of Surprise Medical Bills In The Emergency Room
Opponents of the role of consumers and markets in health care have one go-to argument above all others: that you can’t shop for health care when you’re unconscious. The rising […]
Two Maryland bills are the state’s latest attempt to rein in drug prices
Even as Congress holds hearings and the White House proposes updating rules for drug pricing, Maryland and some other states are also searching for ways to make prescription medications more […]
Arizona Law Restricts Tests for Fentanyl [Video]
Fentanyl test strips can detect the presence of the deadly drug in other drugs, such as OxyContin. But the strips could be considered drug paraphernalia under Arizona law. Faculty Associate Susan […]
In Kensington, police offer drug users help instead of criminal charges
As Philadelphia works to connect more people in Kensington who struggle with opioid addiction to health care and social services, it’s getting help from an unlikely partner: the Philadelphia Police […]
Giant hospital system’s charity status challenged
Pennsylvania Attorney General Josh Shapiro accused a major nonprofit hospital system and health insurer of failing to fulfill its charitable mission Thursday, taking a step into a bruising, years-long regional […]
Congress starts to go after big pharma
Congress on Tuesday jumped into its first round of hearings on drug prices for the year, vowing to take action on a problem that the president and the public see […]
As small hospitals ally with big ones, do patients benefit?
To expand their reach, flagship hospitals including Mayo, the Cleveland Clinic and Houston’s MD Anderson Cancer Center have signed affiliation agreements with smaller hospitals around the country. Gerard Anderson is quoted.
Secretive ‘rebate trap’ keeps generic drugs for diabetes and other ills out of reach
In a practice that policy experts say smothers competition and keeps prices high, drug companies routinely make hidden pacts with middlemen that effectively block patients from getting cheaper generic medicines. […]
Secretive ‘Rebate Trap’ Keeps Generic Drugs For Diabetes and Other Ills Out of Reach
Drug companies routinely make hidden pacts with middlemen that effectively block patients from getting cheaper generic medicines. Faculty Associate Gerard Anderson is quoted.